Urinary Incontinence – 2018 Pipeline Insight Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Urinary
Incontinence – Pipeline Insight, 2018”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

This report offers a comprehensive insight of the pipeline (under
development) therapeutics scenario and growth prospects across Urinary
Incontinence development.
The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.


Scope

  • The report provides a snapshot of the pipeline development for Urinary
    Incontinence
  • The report covers pipeline activity across the complete product
    development cycle i.e. clinical, pre-clinical and discovery stages for
    Urinary Incontinence
  • The report provides pipeline product profiles which includes product
    description, developmental activities, licensors & collaborators and
    chemical information
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development, route of administration, and molecule
    type for Urinary Incontinence
  • The report also covers the dormant and discontinued pipeline projects
    related to Urinary Incontinence
Companies Featured

  • Astellas Pharma Inc.
  • Celogos
  • Cook MyoSite Incorporated
  • FemmePharma Global Healthcare Inc.
  • GTx Inc.
  • Innovacell Biotechnologie AG
  • Ipsen S.A.
  • Outpost Medicine Limited
  • Taiho Pharmaceutical Co. Ltd.
  • Takeda Pharmaceutical Company Limited
  • TheraVida Inc.

Key Topics Covered

1. Report Introduction

2. Urinary Incontinence Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Urinary Incontinence

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3t8jxw/urinary?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Urological
Disorders Drugs